Ozuriftamab provides a monoclonal antibody platform for cancer and antibody research and specifically supports studies of tumor-associated antigen recognition, antibody-mediated cellular targeting, and antibody characterization. Researchers can use it to investigate antigen binding and cellular responses in experimental models expressing its intended target.
Key Features and Benefits
- ROR2-Targeting Antibody: Recognizes receptor tyrosine kinase-like orphan receptor 2 (ROR2), a cell-surface protein specifically associated with tumor progression.
- Conditionally Active Antibody: Designed to exhibit enhanced ROR2 binding under acidic conditions specifically associated with the tumor microenvironment.
- Tumor-Selective Recognition: Supports investigation of antibody binding under tumor-associated versus physiological pH conditions.
- ROR2 Recognition: Enables studies of ROR2 expression, antibody binding, and antigen-specific cellular interactions.
- ADC Development Platform: Provides the targeting antibody component associated with Ozuriftamab Vedotin (BA3021), an investigational ROR2-directed ADC.
- Tumor Microenvironment Research: Supports investigation of pH-dependent antibody activity and conditional antigen recognition.
- Cellular Internalization Research: Useful specifically for studying antibody uptake and intracellular trafficking in ROR2-expressing cells.
- Antibody Engineering Research: Supports investigation of conditionally active antibody design and tumor-selective targeting strategies.
Applications
- Head and Neck Cancer Research: Supports investigation of ROR2-directed antibody targeting in head and neck squamous cell carcinoma models.
- Melanoma Research: Useful for studying ROR2 expression and antibody recognition in melanoma models.
- Triple-Negative Breast Cancer Research: Supports evaluation of ROR2-targeted antibody strategies in relevant breast cancer models.
- ROR2-Positive Cancer Research: Enables investigation of antigen expression and antibody interactions in ROR2-expressing tumors.
- Tumor Microenvironment Research: Supports studies of pH-dependent antibody binding under acidic tumor-associated conditions.
- ADC Research: Provides a targeting antibody platform for investigating ROR2-directed payload conjugation and delivery.
- Antibody Binding Assays: Useful for evaluating antigen recognition, binding specificity, and pH-dependent target engagement.
- Cellular Internalization Studies: Supports investigation of antibody uptake and intracellular trafficking in ROR2-expressing cells.
- Comparative Antibody Research: Useful for comparing conditionally active antibodies with conventional tumor-targeting antibody platforms.
Storage and Handling
- Storage: Store according to the product specification under recommended temperature conditions. Protect from excessive heat and repeated freeze-thaw cycles.
- Handling: Handle using appropriate procedures specifically for monoclonal antibody research materials. Maintain conditions that preserve antibody stability, structural integrity, and antigen-binding activity.
Ozuriftamab provides a ROR2-directed antibody platform for investigating conditionally active tumor targeting and antigen recognition and specifically supports head and neck cancer, melanoma, ROR2-positive tumor, antibody engineering, and ADC research.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.
